Cat.No：GM-88130MAB
Product：Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
Cat.No：GM-88130MAB
Product：Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
GM-88130MAB-1mg / 1 mg
GM-88130MAB-5mg / 5 mg
GM-88130MAB-25mg / 5 mg * 5 vials
GM-88130MAB-50mg / 50 mg
GM-88130MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | CD3&CD20 |
Clone | Epcoritamab |
Alternative Names | CD3: ALPS5,CD,CD152,CELIAC3,CTLA-4,GRD4, GSE, IDDM12 CD20: CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Source/Isotype | Human IgG1 K214R/L234F/L235E/D265A /D356E/L358M/delta447K kappa; Human IgG1 K214R/L234F/L235E/D265A/D356E/L358M/delta447K lambda2 |
Application | Activation assay |
Description | Epcoritamab (also known as EP-C1 or ABBV-181) is a novel bispecific antibody that primarily targets the B cell surface antigens CD3 and CD20. By bringing T cells and tumor cells together, it facilitates the activation of T cells and enhances the anti-tumor immune response. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
Cat.No：GM-88130MAB
Product：Anti-CD3×CD20 hIgG1 Bispecific Antibody (Epcobio)
GM-88130MAB-1mg / 1 mg
GM-88130MAB-5mg / 5 mg
GM-88130MAB-25mg / 5 mg * 5 vials
GM-88130MAB-50mg / 50 mg
GM-88130MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | CD3&CD20 |
Clone | Epcoritamab |
Alternative Names | CD3: ALPS5,CD,CD152,CELIAC3,CTLA-4,GRD4, GSE, IDDM12 CD20: CD279, PD-1, PDCD1, SLEB2, hPD-1, hPD-l, hSLE1 |
Source/Isotype | Human IgG1 K214R/L234F/L235E/D265A /D356E/L358M/delta447K kappa; Human IgG1 K214R/L234F/L235E/D265A/D356E/L358M/delta447K lambda2 |
Application | Activation assay |
Description | Epcoritamab (also known as EP-C1 or ABBV-181) is a novel bispecific antibody that primarily targets the B cell surface antigens CD3 and CD20. By bringing T cells and tumor cells together, it facilitates the activation of T cells and enhances the anti-tumor immune response. |
Formulation | phosphate-buffered solution, pH 7.2-7.4. |
